A clinical briefing for providers on the Apri 28 Day supply situation in 2026 — availability data, prescribing implications, and patient management tools.
If your patients are reporting difficulty filling their Apri 28 Day (Desogestrel 0.15 mg / Ethinyl Estradiol 0.03 mg) prescriptions, the reports are consistent with a broader pattern of intermittent supply disruptions affecting several generic oral contraceptives.
This briefing provides a clinical and logistical overview of the current Apri situation — what's driving it, what it means for prescribing, and what tools are available to help your patients maintain contraceptive continuity.
The supply landscape for generic oral contraceptives has shifted meaningfully since 2022:
Apri is one of several branded generics of Desogestrel 0.15 mg / Ethinyl Estradiol 0.03 mg (reference listed drug: Ortho-Cept). The following products are AB-rated therapeutically equivalent and can be dispensed interchangeably:
Most state pharmacy laws permit generic substitution without a new prescription. However, some patients may report subjective differences between generics (breakthrough bleeding, mood changes). While pharmacokinetically equivalent, inactive ingredient differences can occasionally affect tolerability.
If Desogestrel/Ethinyl Estradiol products are consistently unavailable in your area, consider prescribing an alternative combined oral contraceptive:
For patients who prefer a progestin-only option, Opill (Norgestrel 0.075 mg) is now available over the counter.
Based on pharmacy-level reporting and patient feedback, the availability landscape for Apri 28 Day in early 2026 is as follows:
Under the ACA contraceptive mandate, most commercial insurance plans cover generic oral contraceptives — including Apri and its equivalents — at $0 copay. Medicaid covers oral contraceptives in all states.
For uninsured patients:
Providers can direct uninsured or underinsured patients to our provider's guide to helping patients save on Apri.
Medfinder allows providers and their staff to check real-time pharmacy availability for Apri and equivalent products. This can be integrated into the prescription workflow to identify in-stock pharmacies before sending a prescription electronically.
Consider proactively communicating with patients who are on Apri about:
The oral contraceptive supply landscape is stabilizing but remains vulnerable to disruption. Key factors to watch in 2026:
While there is no official shortage of Apri 28 Day, the disconnect between manufacturer-reported supply and pharmacy-level availability continues to affect patients. Providers play a critical role in maintaining contraceptive continuity by prescribing flexibly, communicating proactively with patients, and leveraging tools like Medfinder.
For patient-facing resources, consider directing your patients to:
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
